Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.
A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.
The research, published in JAMA Oncology, evaluates survival outcomes of a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion.
A study in The Lancet Haematology suggests this combination could become first-line for elderly or unhealthy patients with newly diagnosed AML.
Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma.
A study shows stress may affect certain cellular, cytokine, and chemokine markers in the body of patients with CLL.
A study shows treatment with ibrutinib is superior to chemoimmunotherapy for patients with chronic treatment-naive CLL.
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events.
A study shows expanding access to care through insurance has the potential to improve outcomes in adults with follicular lymphoma.